We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
-7.67%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$103M
AUM Growth
-$42.2M
Cap. Flow
-$26.5M
Cap. Flow %
-25.72%
Top 10 Hldgs %
76.67%
Holding
32
New
7
Increased
5
Reduced
13
Closed
6

Top Buys

Rank Stock Value
1
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$6.28M
2
AMRN
Amarin Corp
AMRN
+$5.39M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$4.78M
4
HTGM
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
+$3.36M
5
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
+$2.33M

Top Sells

Rank Stock Value
1
VNDA icon
Vanda Pharmaceuticals
VNDA
+$18.9M
2
LGND icon
Ligand Pharmaceuticals
LGND
+$13.8M
3
ADMS
Adamas Pharmaceuticals
ADMS
+$4.15M
4
APEN
Apollo Endosurgery, Inc.
APEN
+$3.54M
5
ALIM
Alimera Sciences
ALIM
+$2.24M

Sector Composition

Rank Sector Weight
1 Healthcare 96.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DMAC icon
26
DiaMedica Therapeutics
DMAC
$363M
$28K 0.03%
+13,705
New +$44.3K
MTNB icon
27
Matinas BioPharma
MTNB
$2.13M
– –
-13,372
Closed -$573K
VNDA icon
28
Vanda Pharmaceuticals
VNDA
$314M
– –
-1,341,943
Closed -$18.9M
MOTS
29
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
– –
-117
Closed -$107K
VIVE
30
DELISTED
VIVEVE MED INC
VIVE
– –
-3,403
Closed -$1.29M
SBBP
31
DELISTED
Strongbridge Biopharma plc.
SBBP
– –
-162,244
Closed -$508K
FOMX
32
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
– –
-651,211
Closed -$1.55M
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, Stonepine Capital Management held 32 positions worth $103M, down 29% from $145M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Stonepine Capital Management withdrew a net $26.5M in Q3 2019, closing 6 positions and reducing 13 holdings. Its most notable exit was Vanda Pharmaceuticals, an estimated $18.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier.

Against the trend, Stonepine Capital Management opened a new position in Correvio Pharma Corp. Ordinary Shares (Canada) worth $1.02M.

  • Stonepine Capital Management's largest Q3 2019 buy was Correvio Pharma Corp. Ordinary Shares (Canada): 509,356 shares worth $1.02M.
  • Stonepine Capital Management added most to Oxford Immunotec Global PLC Ordinary Shares in Q3 2019, an estimated $6.28M increase.
  • Stonepine Capital Management's biggest Q3 2019 reduction was Ligand Pharmaceuticals, cutting an estimated $13.8M.
  • Stonepine Capital Management fully exited Vanda Pharmaceuticals in Q3 2019, selling an estimated $18.9M.
  • Stonepine Capital Management's ten largest holdings make up 77% of its $103M portfolio in Q3 2019.
  • Stonepine Capital Management opened 7 new positions and closed 6 in Q3 2019.
  • Stonepine Capital Management's portfolio value fell 29% quarter-over-quarter to $103M.

Based on Stonepine Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.